C2Sense, Inc.
Developer of diagnostic hardware and algorithmic methods that apply computer vision and physics-informed algorithms to improve sensitivity and specificity of point-of-care and at-home assays. Founded as an MIT spinout, the company develops connected reader hardware, AI-enhanced image analysis, luminescent materials and multiplex molecular detection methods and collaborates with diagnostic and pharmaceutical partners.
Industries
N/A
Nr. of Employees
small (1-50)
Patents
Systems and methods for determining a characteristic of an emissive species
US-11796539-B2
View Details
Systems and methods for determining a characteristic of an emissive species
US-11796539-B2
View DetailsProducts
Low-cost connected diagnostic reader for rapid assays
A network-connected reader system intended to acquire assay images and apply algorithmic processing to boost sensitivity and specificity of rapid diagnostic tests.
Multiplex detection method for circulating tumor and cell-free DNA
An R&D-stage multiplex molecular detection capability focused on enhanced detection of circulating tumor DNA and cell-free DNA.
Helios™
A rapid molecular diagnostic platform with unparalleled multiplexed detection and single-copy sensitivity, harnessing padlock probe chemistry, isothermal amplification, and optical readout to detect hundreds to thousands of targets simultaneously.
HALO®
Enables identification of false positives, delineation of non-specific binding, and mitigation of assay defects to improve assay performance without redesign.
Low-cost connected diagnostic reader for rapid assays
A network-connected reader system intended to acquire assay images and apply algorithmic processing to boost sensitivity and specificity of rapid diagnostic tests.
Multiplex detection method for circulating tumor and cell-free DNA
An R&D-stage multiplex molecular detection capability focused on enhanced detection of circulating tumor DNA and cell-free DNA.
Helios™
A rapid molecular diagnostic platform with unparalleled multiplexed detection and single-copy sensitivity, harnessing padlock probe chemistry, isothermal amplification, and optical readout to detect hundreds to thousands of targets simultaneously.
HALO®
Enables identification of false positives, delineation of non-specific binding, and mitigation of assay defects to improve assay performance without redesign.
Services
Custom development and deployment of image-analysis and physics-based algorithms to improve assay performance without assay redesign.
Design and integration of low-cost, network-connected reader hardware for rapid diagnostic assays and connected workflows.
Joint R&D programs to develop and validate multiplex detection methods for circulating tumor DNA and cell-free DNA.
Custom development and deployment of image-analysis and physics-based algorithms to improve assay performance without assay redesign.
Design and integration of low-cost, network-connected reader hardware for rapid diagnostic assays and connected workflows.
Joint R&D programs to develop and validate multiplex detection methods for circulating tumor DNA and cell-free DNA.
Expertise Areas
- Digital diagnostics and connected readers
- Assay signal enhancement and optimization
- Luminescence-based sensing and time-gated measurements
- Point-of-care and at-home diagnostic systems
Key Technologies
- Computer vision for image analysis
- Physics-informed signal processing algorithms
- AI-enhanced diagnostic analytics
- Connected reader hardware and cloud integration
News & Updates
Licensing agreement to commercialize an on-dose authentication (anti-counterfeiting) technology for solid oral dosage pharmaceutical and nutraceutical products.
Announcement of Dr. Kevin Ban joining the company's board as a strategic advisor effective June 1, 2024.
Announcement of Dr. Michael Mina joining the board as an independent director effective May 24, 2024.
Announcement that the company and Princeton BioMeditech received a second NIH RADx award to support development of a digitally-connected at-home diagnostic reader and multiplex antigen test solution.
Peer-reviewed paper demonstrating smartphone-based luminescence imaging as a tool for time-gated measurements.
Awarded NIH RADx Tech funding to accelerate commercialization of a connected at-home diagnostic reader for sensitivity enhancement of an over-the-counter COVID-19/Flu antigen rapid test.
Licensing agreement to commercialize an on-dose authentication (anti-counterfeiting) technology for solid oral dosage pharmaceutical and nutraceutical products.
Announcement of Dr. Kevin Ban joining the company's board as a strategic advisor effective June 1, 2024.
Announcement of Dr. Michael Mina joining the board as an independent director effective May 24, 2024.
Announcement that the company and Princeton BioMeditech received a second NIH RADx award to support development of a digitally-connected at-home diagnostic reader and multiplex antigen test solution.
Peer-reviewed paper demonstrating smartphone-based luminescence imaging as a tool for time-gated measurements.
Awarded NIH RADx Tech funding to accelerate commercialization of a connected at-home diagnostic reader for sensitivity enhancement of an over-the-counter COVID-19/Flu antigen rapid test.